Ironwood Pharmaceuticals, Inc. — 2014 Q3 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2014; filed November 5, 2014. Financial statements are unaudited. Amounts below are in millions unless stated otherwise.
Business context
Ironwood is a GI-focused pharmaceutical company whose lead product, linaclotide, is marketed in the U.S. as LINZESS and in certain European markets as CONSTELLA. U.S. commercialization and development are shared with Actavis; Almirall, Astellas and AstraZeneca are partners in other territories. The company continues to invest in linaclotide and other GI and soluble guanylate cyclase programs.
Financial performance and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Collaborative arrangements revenue | $16.9 | $4.9 | $38.4 | $17.9 |
| Research and development | $25.1 | $23.0 | $74.4 | $79.9 |
| Selling, general and administrative | $28.5 | $30.3 | $87.8 | $94.5 |
| Total costs and expenses | $53.7 | $61.5 | $174.6 | $223.1 |
| Operating loss | $(36.7) | $(56.6) | $(136.2) | $(205.3) |
| Net loss | $(42.0) | $(61.8) | $(152.0) | $(220.8) |
| Basic and diluted loss per share | $(0.30) | $(0.51) | $(1.12) | $(1.93) |
- At September 30, cash and cash equivalents were $51.3 and available-for-sale securities were $213.7, for $265.0 of unrestricted cash, cash equivalents and securities. Current assets were $304.1 and current liabilities $54.1.
- Nine-month operating cash use was $132.8; investing cash use was $94.9, largely reflecting purchases of short-term securities; financing provided $203.4, including $190.4 net proceeds from the February 2014 equity offering. Cash and cash equivalents declined $24.2 to $51.3.
- Notes payable had a carrying value of approximately $174.7, including current and non-current portions; the notes bear 11% interest and are due on or before June 2024. The company expects approximately $9.3 of principal to be current within twelve months.
- No conventional gross or operating margin is presented; revenue is primarily collaboration revenue, and Ironwood continues to report operating and net losses.
Material changes versus prior year
- Q3 collaborative revenue rose $12.0, primarily reflecting a $13.5 increase in Ironwood’s U.S. LINZESS profit share and $1.8 of AstraZeneca license revenue, partly offset by lower API shipments. Nine-month revenue increased $20.5, chiefly due to a $23.7 improvement in the U.S. LINZESS profit share.
- Ironwood’s share of U.S. LINZESS net profit was $5.3 in Q3 2014, versus a $14.4 loss in Q3 2013. For the nine-month period, its share was a $0.3 loss versus a $67.1 loss in 2013.
- Nine-month total costs and expenses fell $48.5, including the absence of 2013 collaboration expense and lower R&D and SG&A. Cost of revenue nevertheless rose $5.8, principally due to an $8.9 inventory write-down.
- Cash, cash equivalents and available-for-sale securities increased by $67.4 from year-end, mainly reflecting the 2014 equity offering, even as cash and cash equivalents alone decreased.
Outlook, commentary and risks
- Management expects continued net losses and substantial R&D and commercialization spending for the foreseeable future. It believes September 30 resources will fund projected operating needs for at least twelve months; this estimate is subject to execution and market risks.
- Almirall suspended CONSTELLA commercialization in Germany in May 2014 after failing to agree on reimbursement pricing. Ironwood cited lower projected European sales as the primary reason for the inventory write-down.
- Actavis completed its acquisition of Forest on July 1, 2014; the North American collaboration remains in effect. Management noted the need to reestablish relationships and confirm alignment following the transaction.
- Other notable items: third-quarter facility subleases generated a $2.6 charge, with expected sublease receipts of $18.0 through 2018 and 2016 under two agreements; a roughly 10% workforce reduction was substantially implemented, with $4.3 of charges recorded in Q1 and no significant further charges expected.
- Major risks include dependence on U.S. LINZESS performance, payer access and pricing, partner execution, manufacturing and supply, clinical and regulatory outcomes, competition, product safety, and ongoing financing needs. The 11% debt and dependence on Actavis collaboration payments for debt service add liquidity risk.
- No numerical revenue or earnings guidance is provided. Subsequent developments described in the filing include Astellas starting a Japanese Phase III trial in October 2014 and Ironwood and Actavis starting a U.S. Phase III trial of a lower linaclotide dose in November 2014.
Important facts for investors to verify
- LINZESS U.S. sales, commercial costs and the basis for the collaboration profit-share settlement, which drives a major portion of reported revenue.
- Cash burn, forecast assumptions behind management’s at-least-twelve-month liquidity assessment, and the timing and source of debt-service payments.
- European reimbursement and launch conditions, including whether CONSTELLA returns to the German market and whether further inventory adjustments are needed.
- Progress, safety and regulatory requirements for linaclotide and pipeline trials, together with supply-chain capacity and partner execution.
- Effects of the 2014 equity issuance and outstanding options on dilution; Class A and Class B share counts and the dual-class voting structure.